
2010-2020:
Evolution of the Longevity Industry
from Zero to 1.0
-
The Industrialization of Longevity
-
The Current State of Longevity Science, Business, Finance, and Practical Applications
-
Longevity Becomes National Priority Item for the Strategic Agenda of Progressive Governments
-
Transforming the Challenge and Deficit of Aging into the Opportunity and Asset of Longevity
-
Defining and De-Risking: Hype vs. Reality
Data Science for Accelerating Aging Research, The Critical Catalyst for Practical Human Longevity and Tangible Investment De-Risking
-
Modern Tools for Investment De-Risking, Accelerating R&D, Safe Self-Experimentation
-
Tangible Metrics and Frameworks for Company Valuation and Due Diligence and the Shift from Model Organism (Mouse) Validation to Human Validation
-
Longevity Economy 2.0 — Biomarkers of Human Longevity as Major Catalyst to Increase Investments and Ensure Sustainable Growth of Longevity Financial Sector
-
DeepTech Engineering Towards the Concept of Digital Human Avatar 1.0, 2.0, 3.0 and 4.0
About the Book: Biomarkers of Human Longevity
Our 2020 book ‘Longevity Industry 1.0: Defining the Biggest and Most Complex Industry in Human History’ distilled the complex assembly of deep market intelligence that Deep Knowledge Group and its Longevity-focused subsidiaries (including Longevity.Capital and Aging Analytics Agency) have developed over the past 8 years into a full-scope understanding of the
global Longevity Industry.
That book placed particular emphasis on the power that Biomarkers of Human Longevity have to serve as a major catalyst and accelerator of short-term practical applications, the translation of theory into practice, and industry de-risking, stabilization and sustainable growth across almost every major aspect, domain, and driving force of the Global Longevity MegaTrend, from business to scientific R&D, personal health optimization and Practical Human Longevity, the Longevity Financial Industry, investment decision-making, Longevity Industrialization, and Longevity Politics, Policy and Governance. Both the increasing amount of tangible developments that have occurred within this domain since the release of ‘Longevity Industry 1.0’ in September 2020, as well as the systematically increasing need for Longevity Industry participants and stakeholders of all kinds - scientists, entrepreneurs, investors, financiers and policy-makers to being on-boarding and utilizing Biomarkers of Human Longevity within their strategic decision-making processes, has led to the decision that the time has come for a dedicated book on this topic.

Biomarkers of Human Longevity - Foreword by Dmitry Kaminskiy
There is perhaps no other single technology or industry subsector, with the exception of AI, that has more potential to accelerate the realization of real-world impacts in Longevity across the full scope of its sectors and domains - industry, policy, investoment, entrepreneurship, policy and governance - than Biomarkers of Human Longevity. It is, quite literally, the key to achieving substantial real-world impact in the translation of Longevity theory into practice in the next several years, applying equally to individuals, scientists, entrepreneurs, investors and even governments.
Similarly, there are few other technologies and industry driving factors that find themselves the subject of so many differing opinions in terms of what should be definitionally encompassed by Biomarkers of Longevity, how they should be aggregated and validated both on an individual and population level, and how they can or should be applied in practice, both logistically, as well as with what specific end goals and practical impacts in mind.
Given the unique confluence of Biomarkers of Human Longevity’s disruptive impact and accelerative potential, on the one hand, and the high degree of disharmonization in terms of what they are and how they could and should be used, on the other hand, it is clear to me that there is a pressing unmet need for the production of a dedicated book that takes Biomarkers of Longevity as its central concern and major fulcrum, identifying the true potential that this technology has to increase individual and national Health-Adjusted Life Expectancy (HALE) and Quality-Adjusted Life Expectancy (QALY), optimize strategic decision-making for start-ups and corporations, de-risk investment, provide for the first time a tangible framework for company valuation, due diligence based on human validation, enable reliable forecasting clinical outcomes, serve as an effective platform for safe self-experimentation and personalized therapeutic fine-tuning, and pave the way for a much more tangible, stable and scalable Global Longevity Industry, where Longevity’s socially-inclusive humanitarian impact is maximized and its potential ethical and socioeconomic concerns are neutralized.
Deep Knowledge Group and its Longevity-focused subsidiaries and affiliates, including its analytical subsidiary Aging Analytics Agency, its specialized investment arm Longevity.Capital, its portfolio companies Longevity Banking Card and Longevity Financial Advisors and the international non-profit consortium Longevity.International, have prioritized the pressing need and the extreme potential of Biomarkers of Human Longevity (and integrated them in various ways into its overall scope of activities and strategic agenda) for several years now, and are expertly positioned to provide a tangible understanding of the major challenges and opportunities to be faced within this domain, and how they can be applied by individuals, institutions and even entire governments in order to achieve their maximum benefits while neutralizing potential pitfalls and issues.
In this book, I will distill the major conclusions, frameworks and forecasts developed and applied by Deep Knowledge Group on this matter with the overall aim of sharing some of our own key principles on how this technology can be effectively applied to optimize strategic decision-making, showing exactly how Biomarkers of Human Longevity is one of the most prospective market-ready tools for achieving tangible short-term results in personal Practical Human Longevity, making tangible Longevity investment decision-making and de-risking, re-tuning the business models of financial corporations (insurance companies, pension funds, and investment banks) at the intersection of the Opposed MegaTrends of Aging Population vs National Healthy Longevity.
Chapter 1: Biomarkers of Human Longevity as the Industry’s Major Critical Catalyst for Accelerating Practical Results in Aging Research Needed for Industry Growth


Chapter 1 presents an overview of the ways in which Biomarkers of Human Longevity will serve as the major catalyst for short-term change, development and harmonization within the Longevity Industry, capable of optimizing the strategies and practices of Longevity companies, investors and policy makers and enabling the first tangible, real-world impacts in the translation of Longevity science and theory into practice of Healthy Human Longevity.
Biomarkers of Longevity: Distribution by Amplitude Level
